Study #2023-0502
A phase 1, multicenter, open-label study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (BMS-986393) in novel combinations in participants with relapsed and/or refractory multiple myeloma and determine the recommended dose for each add-on investigational component
MD Anderson Study Status
Enrolling
Treatment Agent
BMS-986393, Alnuctamab, Mezigdomide, Iberdomide, Elranatamab, Dexamethasone
Description
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Multiple Myeloma
Study phase:
Phase I
Physician name:
Krina Patel
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.?